var title_f5_12_5312="Oropharyngeal candidiasis";
var content_f5_12_5312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharyngeal candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The buccal mucosa is involved here in the pseudomembranous form of oropharyngeal candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5312=[""].join("\n");
var outline_f5_12_5312=null;
var title_f5_12_5313="Doppler estimation of RA RV gradient";
var content_f5_12_5313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler echocardiographic assessment of tricuspid regurgitation and the estimation of the gradient between right ventricle and right atrium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the presence of tricuspid regurgitation a continuous wave Doppler can be passed from the apex to base across the tricuspid valve in the apical four chamber view (panel A) and the Doppler shift caused by the tricuspid regurgitation jet (TR) displayed (panel B). In this example, the peak velocity of the TR jet is 3 m/sec, which, by the Bernoulli equation, represents a 36 mmHg gradient (= 4 x 3 x 3) between right ventricle (RV) and right atrium (RA). If the RA pressure is known or can be estimated, the sum of RA pressure and the RA to RV gradient is equal to the peak pulmonary artery systolic pressure (assuming no pulmonary stenosis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5313=[""].join("\n");
var outline_f5_12_5313=null;
var title_f5_12_5314="Atopic dermatitis papular PI";
var content_f5_12_5314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous papules are present on the hands of this patient with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5314=[""].join("\n");
var outline_f5_12_5314=null;
var title_f5_12_5315="Proximal sugar tong splint";
var content_f5_12_5315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Proximal sugar tong splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Application of the proximal sugar tong splint is shown in three steps. (A) Position the plaster. (B) Secure the splint in place. (C) Add a sling for support.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaw, DC, Heckman, JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391. Copyright &copy; 1984 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5315=[""].join("\n");
var outline_f5_12_5315=null;
var title_f5_12_5316="Ischemic colitis on colonoscopy";
var content_f5_12_5316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ischemic colitis on colonoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of ischemic colitis may reveal continuous necrosis and mucosal friability that resembles ulcerative colitis (left panel); discrete ulcers with surrounding edema may also be seen (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5316=[""].join("\n");
var outline_f5_12_5316=null;
var title_f5_12_5317="Endocarditis due to coagulase-negative staphylococci";
var content_f5_12_5317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endocarditis due to coagulase-negative staphylococci",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5317/contributors\">",
"     JoAnn M Tufariello, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5317/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/12/5317/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulase-negative staphylococci (CoNS) are a major constituent of human skin commensal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Once considered relatively avirulent and probably a contaminant when isolated from a clinical specimen, these organisms have become increasingly recognized as agents of clinically significant nosocomial bloodstream infections. Patients at particular risk include those with prosthetic valves, pacemakers, intravascular catheters, or other foreign bodies, as well as immunocompromised hosts. These infections are inherently difficult to treat given the propensity of these organisms to colonize foreign material to form a biofilm, and to display resistance to multiple antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will emphasize the issues specific to both native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE) caused by CoNS. General discussions related to the diagnosis and treatment of infective endocarditis and to the microbiology, pathogenesis, epidemiology, and antibiotic resistance patterns of CoNS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=see_link\">",
"     \"Treatment of infections due to coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, coagulase-negative staphylococci (CoNS) were uncommon causes of native valve endocarditis (NVE), accounting for approximately 1 to 5 percent of cases. However, CoNS are emerging as an important cause of NVE in both community and healthcare settings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In addition, CoNS is the most frequent cause of prosthetic valve endocarditis (PVE) within the first year after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Native valve endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native valve endocarditis (NVE) has been considered primarily a community-acquired infection, with 65 to 75 percent of patients in most series having an underlying congenital or acquired cardiac abnormality, although healthcare-associated cases are becoming increasingly common [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The clinical presentation of NVE caused by CoNS is indistinguishable from infective endocarditis due to viridans streptococci: fever, weakness, weight loss, and anorexia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/7\">",
"     7",
"    </a>",
"    ]. However, one-quarter to one-third of patients exhibit peripheral stigmata, such as Osler's nodes, Janeway lesions, and splinter hemorrhages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter, multinational study of adults from the International Collaboration on Endocarditis Merged Database found that 99 of 1504 cases of NVE (6.6 percent) were caused by CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/4\">",
"     4",
"    </a>",
"    ]. When compared with patients with NVE caused by Staphylococcus aureus in the database, patients with CoNS had the following significant differences:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower rates of brain embolization (5.5 versus 24 percent)",
"     </li>",
"     <li>",
"      Higher rates of intracardiac abscess formation (15 versus 8.2 percent)",
"     </li>",
"     <li>",
"      Higher rates of surgical intervention (54 versus 35 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When compared with patients with NVE due to viridans group streptococci, patients with CoNS were significantly more likely to have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nosocomial endocarditis (40 versus 1 percent)",
"     </li>",
"     <li>",
"      A long-term intravascular catheter (20 versus 1 percent)",
"     </li>",
"     <li>",
"      Heart failure (49 versus 31 percent), intracardiac abscess (15 versus 8 percent), and pulmonary embolus (5 versus 0.5 percent)",
"     </li>",
"     <li>",
"      A higher rate of surgical intervention (54 versus 35 percent)",
"     </li>",
"     <li>",
"      A higher rate of in-hospital mortality (19 versus 6.6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The emerging association between NVE due to CoNS and healthcare acquisition was further validated in the International Collaboration on Endocarditis Prospective Cohort Study, a large prospective multinational investigation in which CoNS were responsible for approximately 8 percent of NVE cases not associated with injection drug use, and nearly one-half of cases (49 percent) were acquired in the healthcare setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with NVE due to CoNS had a longer duration of symptoms prior to diagnosis as compared with patients with NVE due to S. aureus; despite this apparent delay in diagnosis, embolic events were less frequent among patients with NVE caused by CoNS. When compared with patients with NVE due to S. aureus, a larger proportion of patients with NVE due to CoNS had a pacemaker or implantable defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/5\">",
"     5",
"    </a>",
"    ] . &nbsp;",
"   </p>",
"   <p>",
"    As with other causes of NVE, laboratory abnormalities including anemia, elevated erythrocyte sedimentation rate, and leukocytosis are common. In one study, vegetations were demonstrated by echocardiogram in 89 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/5\">",
"     5",
"    </a>",
"    ]. In a review of 21 patients, 14 developed complications including systemic embolization, heart failure, or new conduction system abnormalities, and nine required surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of isolates are S. epidermidis, although a variety of other species can be causative agents, including S. lugdunensis, S. hominis, S. capitis, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ]. Although most patients respond to antibiotic therapy, mortality rates of 13 to 25 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/4,6,9,10\">",
"     4,6,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staphylococcus lugdunensis is an aggressive pathogen in the setting of NVE. It is a commensal species, frequently isolated from the skin perineum. Unlike other CoNS, it is usually susceptible to most antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In one series of 11 cases of S. lugdunensis IE, native valves were in involved in eight cases; valve destruction with abscess formation was observed in one-half of cases, with a mortality rate of 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/14\">",
"     14",
"    </a>",
"    ]. In another report, four patients presented with rapidly progressive valve destruction requiring prompt valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=see_link\">",
"     \"Staphylococcus lugdunensis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment regimens for NVE due to CoNS are identical to those for coagulase-positive staphylococci endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prosthetic valve endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion will review only issues related to CoNS-induced PVE. More general issues related to PVE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CoNS are the second most common cause of PVE, after S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a series of 69 cases of PVE due to CoNS, 33 occurred between 60 and 365 days and 82 percent of strains were S. epidermidis; 57 percent underwent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/17\">",
"     17",
"    </a>",
"    ]. Early cases occurring within the first year are thought to result from introduction of bacteria at the time of surgery.",
"   </p>",
"   <p>",
"    The infecting isolates in early PVE usually have a phenotype characteristic of nosocomial acquisition. CoNS have been isolated from numerous sources in the operating room including bypass equipment, bone saws and the prosthesis itself, and surgeons have been implicated as the source of contamination in point-source outbreaks for both wound infections and PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early PVE due to CoNS is often locally destructive. In one series of 55 patients, prosthetic valve dysfunction due to annular infection was found in 38 patients and perivalvular extension resulting in abscess formation in 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5317/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main challenge in interpreting blood cultures positive for CoNS in patients with PVE is distinguishing infection from contamination. Obtaining multiple blood cultures, separated over time, with assiduous attention to sterile technique to minimize culture contamination, is crucial in making this distinction. If a patient with a prosthetic valve has sporadically positive cultures, techniques for determining the clonal origin of CoNS isolates should be applied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality associated with PVE remains high despite earlier diagnosis of infection and the use of a combined surgical and medical approach for early infections. Treatment choices for staphylococcal PVE are the same regardless of whether the pathogen is coagulase-negative or S. aureus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections of cardiac pacemakers and implantable cardioverter-defibrillators are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85356585\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulase-negative staphylococci (CoNS) are a major constituent of human skin commensal flora. Once considered relatively avirulent and probably a contaminant when isolated from a clinical specimen, these organisms have become increasingly recognized as agents of clinically significant nosocomial bloodstream infections.(See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at particular risk for CoNS endocarditis include those with prosthetic valves, pacemakers, intravascular catheters, or other foreign bodies, as well as immunocompromised hosts. These infections are inherently difficult to treat given the propensity of these organisms to colonize foreign material and to display resistance to multiple antibiotics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Historically, CoNS were uncommon causes of native valve endocarditis (NVE), accounting for approximately 1 to 5 percent of cases. However, CoNS are emerging as an important cause of NVE in both community and healthcare settings. In addition, CoNS is the most frequent cause of prosthetic valve endocarditis (PVE) within the first year after surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NVE is primarily a community-acquired infection, with 65 to 75 percent of patients in most series having an underlying congenital or acquired cardiac abnormality, although healthcare-associated cases are becoming increasingly common. The clinical presentation of NVE caused by CoNS is indistinguishable from infective endocarditis due to viridans streptococci: fever, weakness, weight loss, and anorexia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Native valve endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CoNS are the most common cause of PVE, accounting for approximately one-third of cases within the first year and only about 10 percent of later cases. The infecting isolates in early PVE usually have a phenotype characteristic of nosocomial acquisition. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prosthetic valve endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment regimens for endocarditis due to CoNS are identical to those for Staphylococcus aureus endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/1\">",
"      Roth RR, James WD. Microbial ecology of the skin. Annu Rev Microbiol 1988; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/2\">",
"      Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science 2009; 324:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/3\">",
"      Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/4\">",
"      Chu VH, Cabell CH, Abrutyn E, et al. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2004; 39:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/5\">",
"      Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis 2008; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/6\">",
"      Caputo GM, Archer GL, Calderwood SB, et al. Native valve endocarditis due to coagulase-negative staphylococci. Clinical and microbiologic features. Am J Med 1987; 83:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/7\">",
"      Whitener C, Caputo GM, Weitekamp MR, Karchmer AW. Endocarditis due to coagulase-negative staphylococci. Microbiologic, epidemiologic, and clinical considerations. Infect Dis Clin North Am 1993; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/8\">",
"      Petti CA, Simmon KE, Miro JM, et al. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol 2008; 46:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/9\">",
"      Williams DN, Peterson PK, Verhoef J, et al. Endocarditis caused by coagulase-negative staphylococci. Infection 1979; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/10\">",
"      Geraci JE, Hanson KC, Giuliani ER. Endocarditis caused by coagulase-negative staphylococci. Mayo Clin Proc 1968; 43:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/11\">",
"      Herchline TE, Ayers LW. Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol 1991; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/12\">",
"      Zinkernagel AS, Zinkernagel MS, Elzi MV, et al. Significance of Staphylococcus lugdunensis bacteremia: report of 28 cases and review of the literature. Infection 2008; 36:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/13\">",
"      Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/14\">",
"      Vandenesch F, Etienne J, Reverdy ME, Eykyn SJ. Endocarditis due to Staphylococcus lugdunensis: report of 11 cases and review. Clin Infect Dis 1993; 17:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/15\">",
"      Lessing MP, Crook DW, Bowler IC, Gribbin B. Native-valve endocarditis caused by Staphylococcus lugdunensis. QJM 1996; 89:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/16\">",
"      Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/17\">",
"      Chu VH, Miro JM, Hoen B, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. Heart 2009; 95:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/18\">",
"      van den Broek PJ, Lampe AS, Berb&eacute;e GA, et al. Epidemic of prosthetic valve endocarditis caused by Staphylococcus epidermidis. Br Med J (Clin Res Ed) 1985; 291:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/19\">",
"      Boyce JM, Potter-Bynoe G, Opal SM, et al. A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery. J Infect Dis 1990; 161:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5317/abstract/20\">",
"      Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2137 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5317=[""].join("\n");
var outline_f5_12_5317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H85356585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85356585\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=related_link\">",
"      Staphylococcus lugdunensis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=related_link\">",
"      Treatment of infections due to coagulase-negative staphylococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_12_5318="Inflamm follicle PI";
var content_f5_12_5318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory follicle response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    How acne develops. Inflammatory response in follicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5318=[""].join("\n");
var outline_f5_12_5318=null;
var title_f5_12_5319="Acetaminophen and codeine: Pediatric drug information";
var content_f5_12_5319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and codeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10328?source=see_link\">",
"    see \"Acetaminophen and codeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=see_link\">",
"    see \"Acetaminophen and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13114313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capital&reg; and Codeine;",
"     </li>",
"     <li>",
"      Tylenol&reg; with Codeine No. 3;",
"     </li>",
"     <li>",
"      Tylenol&reg; with Codeine No. 4",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ratio-Emtec;",
"     </li>",
"     <li>",
"      ratio-Lenoltec;",
"     </li>",
"     <li>",
"      Triatec-30;",
"     </li>",
"     <li>",
"      Triatec-8;",
"     </li>",
"     <li>",
"      Triatec-8 Strong;",
"     </li>",
"     <li>",
"      Tylenol Elixir with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 1;",
"     </li>",
"     <li>",
"      Tylenol No. 1 Forte;",
"     </li>",
"     <li>",
"      Tylenol No. 2 with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 3 with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 4 with Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10328?source=see_link\">",
"      see \"Acetaminophen and codeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Analgesic:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be titrated to appropriate analgesic effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Codeine: 0.5-1 mg codeine/kg/dose every 4-6 hours; maximum dose: 60 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acetaminophen: 10-15 mg/kg/dose every 4-6 hours; do",
"     <b>",
"      not",
"     </b>",
"     exceed 5 doses in 24 hours; maximum daily dose: 90 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     not to exceed 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s labeling: Oral solution (120 mg acetaminophen and 12 mg codeine/5 mL) :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     3-6 years: 5 mL 3-4 times daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     7-12 years: 10 mL 3-4 times daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;12 years: 15 mL every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 1-2 tablets every 4 hours; maximum dose: 12 tablets/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Codeine: 30-60 mg/dose every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acetaminophen: Maximum: 4000 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [C-V]: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL (5 mL, 10 mL, 12.5 mL, 15 mL, 120 mL, 480 mL) [contains alcohol 7%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [C-V] (Capital&reg; and Codeine): Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL (480 mL) [alcohol free; contains propylene glycol, sodium benzoate; fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [C-III]: Acetaminophen 300 mg and codeine phosphate 15 mg; acetaminophen 300 mg and codeine phosphate 30 mg; acetaminophen 300 mg and codeine phosphate 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; with Codeine No. 3: Acetaminophen 300 mg and codeine phosphate 30 mg [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; with Codeine No. 4: Acetaminophen 300 mg and codeine phosphate 60 mg [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F129512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III; C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI upset; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of mild to moderate pain (FDA approved in ages &ge;3 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; may be confused with atenolol, timolol, Tylox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       T3 is an error-prone abbreviation (mistaken as liothyronine)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Codex: Brand name for acetaminophen/codeine [Brazil], but also the brand name for",
"       <i>",
"        saccharomyces boulardii",
"       </i>",
"       [Italy]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Codex [Brazil] may be confused with Cedax brand name for ceftibuten [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F129516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, dysphoria, euphoria, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Histamine release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Antidiuretic hormone release, biliary tract spasm, bradycardia, hypotension, intracranial pressure increased, physical and psychological dependence, respiratory depression, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, codeine phosphate, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with adrenal insufficiency (Addison&rsquo;s disease ); biliary tract impairment; CNS depression/coma; prostatic hyperplasia; urinary stricture; thyroid dysfunction; or severe liver, pulmonary, or renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use caution when combining with other CNS depressants (eg, centrally acting antiemetics, general anesthetics, phenothiazines, sedative-hypnotics) as there may be additive CNS effects. If combined therapy is needed, consider reducing the dose of one or both agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with two or more copies of the variant CYP2D6*2 allele (ie, CYP2D6 \"ultra-rapid metabolizers\"); these patients may have extensive conversion of codeine to morphine with resultant increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Although several case reports of acetaminophen-associated hemolytic anemia have been reported in patients with G-6-PD deficiency, a direct cause and effect relationship has not been well established (concurrent illnesses such as fever or infection may precipitate hemolytic anemia in patients with G-6-PD deficiency); therefore, acetaminophen is generally thought to be safe when given in therapeutic doses to patients with G-6-PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen may cause severe hepatotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day in adults). Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients. Do not exceed maximum daily doses; consider acetaminophen content of all products (prescription and OTC), including combination products when evaluating the total daily dose of acetaminophen; adults ingesting &gt;4 g/day of acetaminophen should seek medical attention immediately.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity and anaphylactic reactions have been reported with acetaminophen and codeine; use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone); discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Codeine may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Respiratory depression may occur even at therapeutic dosages; use with extreme caution in patients with respiratory diseases including asthma, emphysema, COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function. Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. May cause hypotension; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Codeine may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures. Warn patients of possible impairment of alertness or physical coordination. Concurrent use of agonist/antagonist analgesics (ie, pentazocine, nalbuphine, and butorphanol) may precipitate withdrawal symptoms and/or reduce analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting. High potential for abuse; healthcare providers should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some tablets contain metabisulfite which may cause allergic reactions in susceptible individuals. Oral solution contains alcohol (7%). Suspension contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use suspensions containing propylene glycol with caution in neonates. Suspension contains and other liquid products may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of acetaminophen and codeine products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate of absorption of acetaminophen may be decreased when given with food high in carbohydrates",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5182920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13371991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, mental status, blood pressure, bowel function; signs of misuse, abuse, and addiction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=see_link\">",
"      see \"Acetaminophen and codeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use if allergy to acetaminophen and/or opioid exists or if liver disease is present. Increase fluid and fiber intake to avoid constipation. Avoid alcohol. Codeine may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tylenol&reg; With Codeine elixir contains saccharin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/12/5319/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan K and Chang J, \"Neonatal Abstinence Syndrome Due to Codeine,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1997, 76(1):F59-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/12/5319/abstract-text/9059191/pubmed\" id=\"9059191\" target=\"_blank\">",
"        9059191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Cairns J, Chitayat D, et al, \"Pharmacogenetics of Morphine Poisoning in a Breastfed Neonate of a Codeine-Prescribed Mother,\"  Lancet, 2006, 368(9536):704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/12/5319/abstract-text/16920476/pubmed\" id=\"16920476\" target=\"_blank\">",
"        16920476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds EW, Riel-Romero RM, and Bada HS, \"Neonatal Abstinence Syndrome and Cerebral Infarction Following Maternal Codeine Use During Pregnancy,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 2007, 46(7):639-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/12/5319/abstract-text/17704497/pubmed\" id=\"17704497\" target=\"_blank\">",
"        17704497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and H&auml;gg S, \"Analgesics and Breast-Feeding: Safety Considerations,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/12/5319/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration Center for Drug Evaluation and Research, \"FDA Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead to Life-Threatening Side Effects in Nursing Babies,\" available at: file://www.fda.gov/cder/drug/advisory/codeine.htm.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13092 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5319=[""].join("\n");
var outline_f5_12_5319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854545\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114313\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129491\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129492\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050776\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050770\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129479\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129463\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129512\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050781\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050780\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129518\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129516\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050784\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050769\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050768\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129472\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050786\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129473\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182920\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371991\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050767\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050783\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050774\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050785\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10328?source=related_link\">",
"      Acetaminophen and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=related_link\">",
"      Acetaminophen and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_12_5320="Control of the lung hilum";
var content_f5_12_5320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Control of the lung hilum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 678px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During resuscitative thoracotomy, control of the pulmonary hilum is obtained by dividing the inferior pulmonary ligament&nbsp;and clamping&nbsp;across the left mainstem bronchus and pulmonary artery and veins. The lung can be twisted clock-wise, which compress the pulmonary&nbsp;vessels against the bronchus, if an appropriate vascular clamp is unavailable.&nbsp;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5320=[""].join("\n");
var outline_f5_12_5320=null;
var title_f5_12_5321="Diagnostic evaluation of food allergy";
var content_f5_12_5321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic evaluation of food allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Wesley Burks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5321/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/12/5321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4048840\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with possible food allergy is a clinical exercise that includes some combination of the following diagnostic tools, although not all of these elements are necessary in every patient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Prick/puncture",
"      </span>",
"      skin testing",
"     </li>",
"     <li>",
"      <em>",
"       In vitro",
"      </em>",
"      testing",
"     </li>",
"     <li>",
"      Gastroenterologic tests",
"     </li>",
"     <li>",
"      Elimination diets",
"     </li>",
"     <li>",
"      Food challenges",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Every evaluation begins with a detailed history and physical examination. The clinical history is",
"    <strong>",
"     critical",
"    </strong>",
"    in the diagnosis of food allergy, since it is used to determine subsequent testing and interpretation of results. The history and physical examination and the various manifestations of food allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general characteristics of the diagnostic tools in patients with suspected food allergy are reviewed here. The sections on skin testing and",
"    <em>",
"     in vitro",
"    </em>",
"    testing are applicable to IgE-mediated food allergies, although the sections on elimination diets, food diaries, and food challenges apply to multiple types of food allergy. Diagnostic tools under development are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will not discuss general gastroenterologic tests that are used in the evaluation of non-IgE mediated food allergy and eosinophilic gastrointestinal disorders, such as endoscopy, colonoscopy, and gastrointestinal biopsy. These procedures and other tests are presented in reviews of the individual disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF ALLERGY TESTS IN DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy testing, in the form of skin testing or",
"    <em>",
"     in vitro",
"    </em>",
"    tests, must always be selected and interpreted in the context of the patient's specific clinical history [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The details of the history are used to generate an estimate of the patient's pre-test probability of having allergic disease. The sensitivity and specificity of tests for individual foods (and other allergens) have been defined for several of the most common foods, as discussed herein. However, these values have not been determined or validated for the majority of foods. Thus, the pre-test probability is essential for effective use of available testing modalities.",
"   </p>",
"   <p>",
"    The way in which the pre-test probability impacts the interpretation of allergy tests is illustrated by the following clinical vignettes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/6\">",
"     6",
"    </a>",
"    ]. Consider three different two year old children presenting for evaluation of egg allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient One has experienced two severe allergic reactions following the isolated ingestion of scrambled egg, requiring and responding to treatment with epinephrine on both occasions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"       \"Food-induced anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient Two has severe atopic dermatitis and eats egg regularly. He has never experienced an apparent acute reaction to egg, although his mother is aware that food allergy can exacerbate this condition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"       \"Role of allergy in atopic dermatitis (eczema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient Three has no history of allergic problems, but her parents think she misbehaves more after eating egg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pediatrician evaluating these children performs",
"    <em>",
"     in vitro",
"    </em>",
"    testing to egg in all three children. In each child, a moderately positive (egg white IgE: 3",
"    <span class=\"nowrap\">",
"     kUA/L;",
"    </span>",
"    ImmunoCAP, Fisher Scientific) result is obtained. However, the interpretation of the result would be different in each case.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient One has a very high pre-test probability of egg allergy, so a moderately positive test is sufficient to validate the clinical suspicion. The patient should be referred to an allergy specialist for confirmatory skin testing, which is more specific (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H17#H17\">",
"       \"Glossary of common biostatistical and epidemiological terms\", section on 'Measures of diagnostic test performance'",
"      </a>",
"      ). If the",
"      <em>",
"       in vitro",
"      </em>",
"      test had been negative, the pediatrician would be correct to question the result and refer the child to an allergy specialist for further evaluation.",
"     </li>",
"     <li>",
"      Patient Two has a moderate pre-test probability, since up to 40 percent of children with moderate to severe atopic dermatitis have underlying food allergy, and egg is a common cause of childhood food allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. In this patient, the positive result is suggestive of true allergy, although further evaluation is needed to demonstrate that egg allergy is contributing to skin inflammation.",
"     </li>",
"     <li>",
"      Patient Three has an extremely low pre-test probability, and the test result is not sufficiently positive to impact the clinician's initial impression. This case also illustrates one of the disadvantages of performing testing in patients whose histories are not consistent with allergic disease, as irrelevant results may confuse the situation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    (or epicutaneous) method of skin testing is commonly used in the evaluation of a suspected IgE-mediated food allergy. Allergy skin testing should only be performed by allergy specialists familiar with these tests and in settings equipped with the necessary medications, equipment, and staff to treat anaphylaxis. Intradermal skin testing should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in the evaluation of food allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H6476491#H6476491\">",
"     \"Overview of skin testing for allergic disease\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prick/puncture skin tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin prick testing is best used to investigate the possibility of an IgE-mediated reaction to a specific food in a patient with a suggestive clinical history (ie, a high pre-test probability) of allergy. It is also highly effective for excluding IgE-mediated allergy, particularly in a patient with a low pre-test probability. Because of the low specificity of skin testing, it should",
"    <strong>",
"     not",
"    </strong>",
"    be used to screen patients for allergy by testing with broad panels of food allergens without regard for clinical history, since this is likely to yield false positive results.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Prick/puncture",
"    </span>",
"    skin tests are highly reproducible and less costly to perform than",
"    <em>",
"     in vitro",
"    </em>",
"    testing. Skin testing causes minimal patient discomfort and yields results within 15 minutes. This type of testing can be safely performed in patients of any age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin of infants may be less reactive, yielding more false negative results, although this difference has not been formally studied. Nevertheless, positive results are commonly obtained in infants with a history consistent with food allergy. Unfortunately, very young children may also have more systemic reactions to skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, skin testing can be performed even in infants and young children, when indicated and with appropriate precautions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Precautions and preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy skin testing is considered a safe procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/11\">",
"     11",
"    </a>",
"    ]. However, systemic, potentially life-threatening, allergic reactions can occur. Thus, it is recommended that this type of testing be performed by allergy specialists trained in the treatment of anaphylaxis and in a setting where full emergency equipment and medications are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H6476491#H6476491\">",
"     \"Overview of skin testing for allergic disease\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following factors should be considered in the decision to perform skin testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin testing should be performed only with caution in patients who, by history, are at high risk for a systemic reaction, such as patients with moderate or severe asthma who have experienced anaphylaxis previously, particularly if their asthma is poorly controlled. The decision to skin test such a patient should be made on an individual basis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of skin testing for allergic disease\", section on 'High risk patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain medications, such as antihistamines, can interfere with skin testing and must be stopped beforehand. Preparations for skin testing are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of skin testing for allergic disease\", section on 'Medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Widespread skin conditions may preclude accurate skin testing. These include dermographism, urticaria, and severe or widespread atopic dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of skin testing for allergic disease\", section on 'Skin conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin testing is not usually performed for several weeks after an episode of anaphylaxis because it has been observed that anaphylaxis can render the skin temporarily nonreactive. The reasons for this refractory period have not been studied, although extensive depletion of surface IgE",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      granule contents within cutaneous mast cells are possible explanations. Full restoration of skin reactivity can take two to four weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of skin testing for allergic disease\", section on 'Recent anaphylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;To perform",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    skin testing, a source of food allergen is applied to the skin, together with appropriate positive (histamine) and negative (saline) controls. One of several commercially-available devices (metal lancets, plastic probes, bifurcated needles) is used to prick through the allergen into the top layer of the skin. Sources of food allergen include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Commercially-prepared food extracts (1:10 or 1:20",
"      <span class=\"nowrap\">",
"       weight/volume",
"      </span>",
"      in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fresh foods (wet foods can be applied directly, dry foods can be made into pastes or slurries)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When fresh foods are used, the lancet can also be used to prick the food and then prick the patient's cleaned skin (\"prick-by-prick\" method). This is commonly used for testing of fresh fruits, as the proteins in fruits are prone to degradation during commercial processing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link&amp;anchor=H26941118#H26941118\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Prick-by-prick skin testing with fresh foods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The food is pricked into the skin to introduce the allergen to cutaneous mast cells. If food-specific IgE antibody is present on the surface of the patient's mast cells, then the cells degranulate, releasing histamine and other mediators that cause localized cutaneous swelling (ie, a wheal). Vasodilation also develops as a result of an axonal reflex (ie, a flare).",
"   </p>",
"   <p>",
"    A skin prick test eliciting a wheal at least three millimeters in diameter, after the saline control is subtracted, is considered positive; anything else is considered negative [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/13\">",
"     13",
"    </a>",
"    ]. General issues regarding the technique of skin prick testing (for foods as well as other allergens) are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin prick testing is highly sensitive, but only moderately specific (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H17#H17\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Measures of diagnostic test performance'",
"    </a>",
"    ). The general sensitivity and specificity of skin prick testing for the diagnosis of food allergy are often estimated to be greater than 90 and approximately 50 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this figure incorporates important variables, including the quality of the extract used and the degree of positivity.",
"   </p>",
"   <p>",
"    The quality of commercially-available skin testing food reagents is generally good, but there is some variability. Extracts of milk, eggs, peanuts, tree nuts, soy, fish, and shellfish are usually reliable. In contrast, commercial extracts of fruits and vegetables are sometimes inadequate because the responsible allergen may be labile and altered during processing.",
"   </p>",
"   <p>",
"    Prick by prick testing with fresh foods, although less convenient, has a higher correlation to clinical reactivity than testing with commercial extracts for many foods. In a study of children with food allergies, for example, concordance between skin testing and challenge was 59 percent for commercial extracts and 92 percent for fresh food [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The larger the wheal, the greater the likelihood of clinical allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the size of the skin test does not correlate with the severity of a reaction. Large positive skin tests in children tested to cow's milk, egg, and peanut, were shown in one study to have excellent positive predictive values for subsequent positive food challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/16\">",
"     16",
"    </a>",
"    ]. In this study, which tested 467 children with a median age of three years using commercial extracts, a peanut skin prick test &gt;8 mm was \"100 percent\" diagnostic for a positive food challenge to peanut (the corresponding reaction for children less than two years of age was &gt;4 mm). These findings were confirmed in a subsequent study of children up to 16 years old with peanut sensitivity, in which a different manufacturer's extracts were used, suggesting the findings may be generalizable to children suspected of having peanut allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar cutoff values have not yet been validated for the other common food allergens or in adults. In addition, these results may not be generalizable to all populations. Additional studies are needed.",
"   </p>",
"   <p>",
"    In contrast, the negative predictive accuracy for skin prick testing to foods is uniformly high. A negative skin test confirms the absence of an IgE-mediated reaction with 90 to 95 percent accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/18\">",
"     18",
"    </a>",
"    ]. Therefore, skin testing is highly useful for excluding IgE-mediated food allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intradermal skin tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradermal skin testing should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in the evaluation of food allergy, since it does not add to the diagnosis and carries a greater risk of inducing a systemic reaction than does prick skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/19\">",
"     19",
"    </a>",
"    ]. Fatalities have been reported with intradermal testing to foods [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/10,20\">",
"     10,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H6477150#H6477150\">",
"     \"Overview of skin testing for allergic disease\", section on 'Fatalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atopy patch tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopy patch testing is another type of skin testing that involves the topical application of a food-containing solution to the skin for 48 hours, and has shown promise in the diagnosis of",
"    <strong>",
"     non-IgE",
"    </strong>",
"    mediated food allergy. However, there are currently no standardized reagents, application methods, or guidelines for interpretation, and this type of testing cannot be recommended outside of research settings. This method is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"     \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IN VITRO TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioallergosorbent tests (RASTs) and fluorescent enzyme immunoassay (FEIA) tests are",
"    <em>",
"     in vitro",
"    </em>",
"    assays used to identify food-specific IgE antibodies in the serum. The commercially available tests currently in use do not employ radioactivity, although the term RAST is often used erroneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunoassays are considered less sensitive than skin prick tests, although the two modalities may be equivalent for certain foods (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H17#H17\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Measures of diagnostic test performance'",
"    </a>",
"    ). Immunoassays are also significantly more costly than skin testing, and the results are not as immediately available. However, immunoassays for food-specific IgE have several useful features.",
"    <em>",
"     In vitro",
"    </em>",
"    tests are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Widely available",
"     </li>",
"     <li>",
"      Unaffected by the presence of antihistamines or other medications",
"     </li>",
"     <li>",
"      Useful in patients with severe anaphylaxis in whom skin testing may carry an unacceptable degree of risk",
"     </li>",
"     <li>",
"      Useful in patients with dermatologic conditions that may preclude skin testing, such as severe atopic dermatitis and dermographism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of immunoassays are reported using percentage, class, or numerical ranks that compare the amount of IgE present in the patient's serum to a standard curve. Higher concentrations of food-specific IgE correlate to an increased likelihood of a reaction upon ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. However, an individual patient with a significant food allergy can have a high, medium, low, or even negative",
"    <em>",
"     in vitro",
"    </em>",
"    test using these systems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/24\">",
"     24",
"    </a>",
"    ]. It is also true that a patient can have a low positive FEIA test for a food to which they are tolerant.",
"   </p>",
"   <p>",
"    Several large studies have used the Phadia&reg; ImmunoCAP fluorescent enzyme immunoassay (CAP-FEIA) system, and so normative results from studies on selected patient groups are available for this specific product. Values obtained with other testing systems are not necessarily interchangeable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/25\">",
"     25",
"    </a>",
"    ]. Very high positive predictive accuracy",
"    <strong>",
"     in children",
"    </strong>",
"    can be achieved using the Phadia&reg; ImmunoCAP system. In a retrospective study of nearly 200 pediatric patients with food allergy, minimum levels of IgE to specific foods were identified that were associated with a 95 percent positive predictive value for clinical food hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/21\">",
"     21",
"    </a>",
"    ]. Approximately 90 percent of these children had atopic dermatitis.",
"   </p>",
"   <p>",
"    The validity of these values in a less selected population was then prospectively evaluated in a study in which the sera of 100 children and adolescents (mean age of 3.8 years, range 0.4 to 14 years) with possible food allergy was assessed for reactivity to egg, milk, peanuts, and fish [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/24\">",
"     24",
"    </a>",
"    ]. The concentrations of specific IgE antibodies were compared with the clinical history and the results obtained by skin testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    double-blind placebo-controlled food challenge (DBPCFC). Based upon the same minimum values obtained in the previous study, positive predictive values of 96, 100, 100, and 100 percent were obtained with the Phadia&reg; CAP-FEIA system for clinical allergies to egg, milk, peanut, and fish, respectively.",
"   </p>",
"   <p>",
"    Subsequent studies have generated somewhat different predictive values, possibly because of variations in the patient populations or testing protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ]. In addition, the predictive values vary with age, such that younger children and infants display symptoms at lower serum levels of food-specific IgE compared with older children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based primarily upon studies performed in the United States in children with a history of food allergy older than two years of age, the 95 percent predictive levels for egg, milk, peanut, tree nuts, and fish are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Egg, 7",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      (2",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      for children less than two years of age)",
"     </li>",
"     <li>",
"      Milk, 15",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      (5",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      for children less than two years of age)",
"     </li>",
"     <li>",
"      Peanut, 14",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"     </li>",
"     <li>",
"      Tree nuts, approximately 15",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"     </li>",
"     <li>",
"      Fish, 20",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a",
"    <strong>",
"     child",
"    </strong>",
"    over two years old with a convincing history of egg allergy has a greater than 95 percent likelihood of experiencing an allergic reaction to egg upon challenge if their egg-specific IgE",
"    <strong>",
"     exceeds",
"    </strong>",
"    7",
"    <span class=\"nowrap\">",
"     kUA/L.",
"    </span>",
"    Therefore, challenge is unnecessary in such children. Equivalent predictive positive levels for soy and wheat have",
"    <strong>",
"     not",
"    </strong>",
"    yet been established. To reiterate, these data were developed in children, and there are currently no recommendations regarding their interpretation in adults with food allergy.",
"   </p>",
"   <p>",
"    Some children with egg allergy may tolerate egg in baked goods, but react on ingestion of lightly cooked egg. Similar findings are seen with milk allergy. In one series, the 95 percent positive predictive values for reacting to raw egg white on challenge were 10",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    for egg white and 6",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    for ovomucoid using the Phadia&reg; ImmunoCAP system. The corresponding levels for patients reacting to heated egg white on challenge were 62 and 20",
"    <span class=\"nowrap\">",
"     kAU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=see_link&amp;anchor=H5#H5\">",
"     \"Egg allergy: Management\", section on 'Dietary recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=see_link&amp;anchor=H3#H3\">",
"     \"Egg allergy: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=see_link&amp;anchor=H7#H7\">",
"     \"Milk allergy: Management\", section on 'Avoidance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=see_link&amp;anchor=H5#H5\">",
"     \"Milk allergy: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, lower food-specific IgE levels are less helpful because food challenge is still frequently required to make a definitive diagnosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    ). This was found in a retrospective study of over 600 food challenges in nearly 400 children, in whom all had food-specific IgE levels measured by CAP-RAST. For milk and egg, approximately 50 percent of children with CAP-RAST values of approximately 2",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    tolerated these foods on challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106817\">",
"    <span class=\"h2\">",
"     Component testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foods are comprised of numerous proteins and an individual with a food allergy may have immune responses of varying degrees to any of them. The potency of individual proteins in a food may relate to their lability. Proteins that are destroyed easily by heating or digestion are less likely to cause significant allergic reactions compared with heat or digestion-stable proteins. Ara h 2, for example, is a peanut seed storage protein that is stable. IgE responses to this protein are associated with severe reactions compared with IgE responses to the peanut protein Ara h 8, which is a labile protein homologous to a protein in Birch tree pollen. An individual with a strong immune response to Ara h 2 and no response to Ara h 8 might be predicted to have a severe peanut allergy compared with a person with no response to Ara h 2 and a modest response to Ara h 8, even though a positive test to whole peanut extract would be positive in both, possibly with the same result. Widespread use of this type of testing for a variety of foods awaits additional studies, because the relationship of the degree of response to each allergen has not yet been adequately studied. This testing is discussed in more detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H19982337#H19982337\">",
"     \"Future diagnostic tools for food allergy\", section on 'Component-resolved diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Basophil histamine release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basophil histamine release (BHR) assays measure histamine release from whole blood basophils, which are exposed to various food antigens and can be used to test for IgE-mediated allergy. Currently, this method provides no additional information beyond standard in vitro and skin testing methods [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/30\">",
"     30",
"    </a>",
"    ]. Basophil activation testing (BAT), a different type of basophil test, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H5#H5\">",
"     \"Future diagnostic tools for food allergy\", section on 'Basophil activation testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRIAL ELIMINATION DIETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"elimination diet\" can be confusing, since it can refer to a diet that is prescribed by a clinician as part of an evaluation for food allergy or to the avoidance that is prescribed once a food allergy is diagnosed. This topic reviews diagnostic elimination diets.",
"   </p>",
"   <p>",
"    There are at least three different types of elimination diets [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One type of elimination diet removes one or several suspect foods from a patient's diet to determine if they are causing or exacerbating a condition. If improvement is noted, then allergy is possible and further objective testing to implicate that food should be pursued. If no improvement is noted with the appropriate period of avoidance, then allergy to that food is unlikely. Trial elimination diets should be limited in duration. A period of two weeks is usually sufficient to see a response in IgE-mediated disorders. Resolution of disorders with non-IgE mechanisms may take weeks. Nutrition must be evaluated in children if such prolonged elimination is prescribed for an important food(s). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=see_link\">",
"       \"Nutritional issues in food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second type of elimination diet that is used rarely involves prescribing an \"oligoantigenic\" diet in which a nutritionally complete selection of foods is allowed and other foods that are commonly implicated in allergic disorders are removed temporarily from the diet. An example of an oligoantigenic diet is one in which the following foods were allowed: rice, lamb, cooked apple, sweet potato, asparagus, spinach, lettuce, olive oil, salt, and sugar [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/31\">",
"       31",
"      </a>",
"      ]. This approach may be useful in the evaluation of patients with chronic conditions, such as atopic dermatitis or chronic urticaria, in which food allergy is questioned, but no specific food can be implicated. Again, it is advisable to involve a nutritionist when eliminating multiple foods from the diet of a growing child. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=see_link\">",
"       \"Nutritional issues in food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A third type of elimination diet involves the use of elemental diets, which are usually achieved through the use of extensively hydrolyzed or amino acid-based formulas. These are used by some allergy specialists in the evaluation of disorders associated with multiple food sensitivities, such as eosinophilic esophagitis. Such diets can have adverse consequences and should only be prescribed with great caution, particularly in infants and children. (See",
"      <a class=\"medical medical_review\" href=\"./dietary-management-of-eosinophilic-esophagitis?source=see_link&amp;anchor=H9242276#H9242276\">",
"       \"Dietary management of eosinophilic esophagitis\", section on 'Elemental diets'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elimination diets are also employed prior to food challenges, to ensure that the food is cleared from the patient's system and is not interfering with the ability to appreciate a reaction. As an example, if a challenge is performed to determine if a food is worsening atopic dermatitis and the patient continues to eat the food up until the challenge, then the skin may already be sufficiently inflamed at baseline that no change is appreciated during the challenge. As a note of caution, a patient may react more dramatically to a food if the food has been eliminated from the diet for some time [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link&amp;anchor=H2#H2\">",
"       \"Oral food challenges for diagnosis and management of food allergies\", section on 'Elimination diets'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link&amp;anchor=H4#H4\">",
"       \"Role of allergy in atopic dermatitis (eczema)\", section on 'Food allergies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of diagnostic elimination diets is influenced by patient and clinician-related variables. Successful elimination of foods requires an understanding of how to approach avoidance of allergens, which necessitates knowledge of label-reading, cross contact and other details. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The interpretation of an elimination diet also requires some skill on the part of the clinician. As an example, although dairy avoidance may reduce symptoms, this could be secondary to various types of cow's milk hypersensitivity or to lactose intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOOD DIARIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food diaries are written records of everything that is ingested by a patient, including all foodstuffs, beverages, condiments, and candies. Although rarely diagnostic on their own, food diaries may be helpful in identifying a food that was overlooked by the patient, a food containing hidden ingredients, or patterns of reactions (eg, in association with exercise, alcohol, or antiinflammatory medications).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FOOD CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral food challenges are structured protocols in which the patient ingests a suspect food under clinician supervision. Food challenges should only be performed by allergy specialists familiar with food-allergic reactions and in settings equipped with the necessary medications, equipment, and staff to treat anaphylaxis. Food challenges are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     UNVALIDATED METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present after having food allergy tests performed that have not been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/3,19,33\">",
"     3,19,33",
"    </a>",
"    ]. These can include food-specific IgG and IgG4 tests, which typically yield multiple positive results and may represent a normal immune response to food.",
"   </p>",
"   <p>",
"    Food-specific IgG4 does not predict true food hypersensitivity, and may actually be a marker of earlier development of tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In one study, children with atopic dermatitis (eczema) and egg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    milk allergy who had higher levels of IgG4 to milk and egg proteins on presentation were more likely to be tolerant to these foods by 4.5 years of age compared with children with lower IgG4 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/37\">",
"     37",
"    </a>",
"    ]. In another study, resolution of cow's milk allergy was associated with increasing IgG4 and decreasing IgE binding to milk protein epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/38\">",
"     38",
"    </a>",
"    ]. This was further confirmed in children with egg allergy who were challenged to egg in baked goods [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/39\">",
"     39",
"    </a>",
"    ]. The children who failed the challenge had higher ovalbumin and ovomucoid",
"    <span class=\"nowrap\">",
"     IgE/IgG4",
"    </span>",
"    ratios compared with the children who passed the challenge. In addition, IgG4 increased in patients who successfully underwent oral immunotherapy for milk or peanut allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Thus, food-specific IgG4 should not be used as a tool to diagnose food allergy and food should not be eliminated from the diet based upon results of these tests [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other types of testing for food allergy that are not supported by scientifically-valid concepts include sublingual or intradermal provocation tests, tests of lymphocyte activation, kinesiology, cytotoxic tests, and electrodermal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5321/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       \"Patient information: Food allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elements in the evaluation of food allergy include history and physical exam followed by some combination of skin testing,",
"    <em>",
"     in vitro",
"    </em>",
"    testing, elimination diets, food diaries, and various types of food challenges.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The history is critical in the diagnosis of food allergy, and is the first step in discerning both the type of food allergy present and the suspected causative food. It is also used to determine the type of testing that is most appropriate and to interpret test results. This essential component of food allergy diagnosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"       \"History and physical examination in the patient with possible food allergy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4048840\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing for food-specific IgE is used only in the diagnosis of IgE-mediated food allergies. Skin testing is more sensitive than",
"      <em>",
"       in vitro",
"      </em>",
"      testing in many cases. It should be performed by an allergy specialist, because of both the risk of anaphylaxis and the skill required for proper interpretation. Skin testing is contraindicated or unreliable in certain subsets of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Skin testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H6477150#H6477150\">",
"       \"Overview of skin testing for allergic disease\", section on 'Fatalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive skin test to a particular food only indicates the",
"      <strong>",
"       possibility",
"      </strong>",
"      that the patient has true allergy to that food. The specificity of skin testing for foods varies from 50 to 95 percent, depending upon the food in question and the patient's pre-test probability of having allergy. Further tests or challenges are usually needed to confirm that the patient is truly reactive to the food upon ingestion. In contrast, a negative skin test result indicates the absence of an IgE-mediated allergy upon subsequent challenge with a 90 to 95 percent predictive accuracy. Further testing or challenge is sometimes indicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of allergy tests in diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE immunoassays are",
"      <em>",
"       in vitro",
"      </em>",
"      assays used to identify food-specific IgE in the serum. These tests are widely available and are unaffected by the presence of medications. Their sensitivity varies among different foods. In at least one system, immunoassays have demonstrated very high positive predictive accuracy",
"      <strong>",
"       in children",
"      </strong>",
"      for several of the major food allergens. Values have been established for egg, milk, peanut, tree nuts, and fish that correspond to a positive predictive accuracy of 95 percent for a reaction on challenge, such that a child with a test result higher than these values, in combination with a suspicion of an allergy to the food, does not require challenge for definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'In vitro testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"       \"Overview of in vitro allergy tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnostic elimination diets are employed in various ways depending on the clinical scenario. Careful attention to nutrition is necessary whenever an essential food is removed from the diet of a growing child. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Trial elimination diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food diaries are written records of everything that is ingested by a patient. They can be helpful in identifying overlooked foods, hidden ingredients, and patterns of reactions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Food diaries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supervised food challenges are sometimes required for the definitive diagnosis of food allergy, with the double-blind, placebo-controlled food challenge (DBPCFC) being the most precise form of challenge. Foods are selected for testing based upon the history and the results of skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <em>",
"       in vitro",
"      </em>",
"      testing. Food challenges should only be performed by allergy specialists familiar with food-allergic reactions and equipped with the necessary medications, equipment, and personnel to treat anaphylaxis and shock. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Food challenges'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are a variety of unvalidated forms of testing for food allergy available in the community. These have no role in the diagnosis of food allergy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Unvalidated methods'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/1\">",
"      Burks AW, Sampson HA. Diagnostic approaches to the patient with suspected food allergies. J Pediatr 1992; 121:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/2\">",
"      Du Toit G, Santos A, Roberts G, et al. The diagnosis of IgE-mediated food allergy in childhood. Pediatr Allergy Immunol 2009; 20:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/3\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/4\">",
"      Burks AW, Jones SM, Boyce JA, et al. NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population. Pediatrics 2011; 128:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/5\">",
"      Fleischer DM, Bock SA, Spears GC, et al. Oral food challenges in children with a diagnosis of food allergy. J Pediatr 2011; 158:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/6\">",
"      American College of Allergy, Asthma, &amp; Immunology. Food allergy: a practice parameter. Ann Allergy Asthma Immunol 2006; 96:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/7\">",
"      Burks AW, James JM, Hiegel A, et al. Atopic dermatitis and food hypersensitivity reactions. J Pediatr 1998; 132:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/8\">",
"      Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/9\">",
"      Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999; 104:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/10\">",
"      Devenney I, F&auml;lth-Magnusson K. Skin prick tests may give generalized allergic reactions in infants. Ann Allergy Asthma Immunol 2000; 85:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/11\">",
"      Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/12\">",
"      Ortolani C, Ispano M, Pastorello EA, et al. Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. J Allergy Clin Immunol 1989; 83:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/13\">",
"      Eigenmann PA, Sampson HA. Interpreting skin prick tests in the evaluation of food allergy in children. Pediatr Allergy Immunol 1998; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/14\">",
"      Ranc&eacute; F, Juchet A, Br&eacute;mont F, Dutau G. Correlations between skin prick tests using commercial extracts and fresh foods, specific IgE, and food challenges. Allergy 1997; 52:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/15\">",
"      Sporik R, Hill DJ, Hosking CS. Specificity of allergen skin testing in predicting positive open food challenges to milk, egg and peanut in children. Clin Exp Allergy 2000; 30:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/16\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/17\">",
"      Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. J Allergy Clin Immunol 2005; 115:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/18\">",
"      Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004; 113:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/19\">",
"      Sicherer SH, Teuber S, Adverse Reactions to Foods Committee. Current approach to the diagnosis and management of adverse reactions to foods. J Allergy Clin Immunol 2004; 114:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/20\">",
"      Lockey RF. Adverse reactions associated with skin testing and immunotherapy. Allergy Proc 1995; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/21\">",
"      Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997; 100:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/22\">",
"      Garc&iacute;a-Ara C, Boyano-Mart&iacute;nez T, D&iacute;az-Pena JM, et al. Specific IgE levels in the diagnosis of immediate hypersensitivity to cows' milk protein in the infant. J Allergy Clin Immunol 2001; 107:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/23\">",
"      Celik-Bilgili S, Mehl A, Verstege A, et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. Clin Exp Allergy 2005; 35:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/24\">",
"      Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/25\">",
"      Wang J, Godbold JH, Sampson HA. Correlation of serum allergy (IgE) tests performed by different assay systems. J Allergy Clin Immunol 2008; 121:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/26\">",
"      Osterballe M, Bindslev-Jensen C. Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship? J Allergy Clin Immunol 2003; 112:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/27\">",
"      Komata T, S&ouml;derstr&ouml;m L, Borres MP, et al. The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age. J Allergy Clin Immunol 2007; 119:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/28\">",
"      Ando H, Mov&eacute;rare R, Kondo Y, et al. Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy. J Allergy Clin Immunol 2008; 122:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/29\">",
"      Perry TT, Matsui EC, Kay Conover-Walker M, Wood RA. The relationship of allergen-specific IgE levels and oral food challenge outcome. J Allergy Clin Immunol 2004; 114:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/30\">",
"      Hamilton RG, Franklin Adkinson N Jr. In vitro assays for the diagnosis of IgE-mediated disorders. J Allergy Clin Immunol 2004; 114:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/31\">",
"      Sicherer SH. Food allergy: when and how to perform oral food challenges. Pediatr Allergy Immunol 1999; 10:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/32\">",
"      David TJ. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child 1984; 59:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/33\">",
"      Beyer K, Teuber SS. Food allergy diagnostics: scientific and unproven procedures. Curr Opin Allergy Clin Immunol 2005; 5:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/34\">",
"      Lemon-Mul&eacute; H, Sampson HA, Sicherer SH, et al. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008; 122:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/35\">",
"      Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/36\">",
"      Matsumoto N, Okochi M, Matsushima M, et al. Peptide array-based analysis of the specific IgE and IgG4 in cow's milk allergens and its use in allergy evaluation. Peptides 2009; 30:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/37\">",
"      Tomici S, Norrman G, F&auml;lth-Magnusson K, et al. High levels of IgG4 antibodies to foods during infancy are associated with tolerance to corresponding foods later in life. Pediatr Allergy Immunol 2009; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/38\">",
"      Savilahti EM, Rantanen V, Lin JS, et al. Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes. J Allergy Clin Immunol 2010; 125:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/39\">",
"      Caubet JC, Bencharitiwong R, Moshier E, et al. Significance of ovomucoid- and ovalbumin-specific IgE/IgG(4) ratios in egg allergy. J Allergy Clin Immunol 2012; 129:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/40\">",
"      Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 2008; 122:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/41\">",
"      Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5321/abstract/42\">",
"      Stapel SO, Asero R, Ballmer-Weber BK, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008; 63:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2396 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5321=[""].join("\n");
var outline_f5_12_5321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4048840\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF ALLERGY TESTS IN DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prick/puncture skin tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Precautions and preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intradermal skin tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atopy patch tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IN VITRO TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6106817\">",
"      Component testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Basophil histamine release",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRIAL ELIMINATION DIETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOOD DIARIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FOOD CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      UNVALIDATED METHODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./dietary-management-of-eosinophilic-esophagitis?source=related_link\">",
"      Dietary management of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=related_link\">",
"      Egg allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=related_link\">",
"      Egg allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=related_link\">",
"      Milk allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=related_link\">",
"      Nutritional issues in food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_12_5322="Approach to the long-term survivor of breast cancer";
var content_f5_12_5322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the long-term survivor of breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Kathryn J Ruddy, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Ann H Partridge, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/12/5322/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/12/5322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H346411016\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to statistics from the International Agency for Research on Cancer (IARC), there are approximately 29 million cancer survivors worldwide as of 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, there are an estimated 14 million cancer survivors as of 2012, a figure that is expected to increase to approximately 18 million in the next 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/2\">",
"     2",
"    </a>",
"    ]. Nearly three million women have a history of breast cancer and constitute over 40 percent of female cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the vast majority of breast cancer survivors are women, approximately 2000 men are diagnosed with breast cancer annually in the United States alone, and most will achieve long-term disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are living for decades beyond cancer experience the normal issues of aging, which are often compounded by the long-term effects of having had cancer and cancer therapy. These patients are at risk for a breast cancer recurrence (which is most common in the first five years but may occur even decades following treatment), a new primary breast cancer, other cancers, and short-term and long-term adverse effects of treatment. Additional issues for cancer survivors relate to psychological, genetic, reproductive, social, and employment concerns. Unfortunately, there is a lack of clear evidence for what constitutes best practices in caring for patients with a history of cancer, and this contributes to wide variation in care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for posttreatment surveillance after primary therapy of breast cancer will be reviewed here. A detailed discussion of the patterns of relapse (ie, locoregional recurrence, second primary breast tumor, metastatic disease) and long-term complications of breast cancer therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general overview of cancer survivorship is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541710487\">",
"    <span class=\"h1\">",
"     DEFINING A CANCER SURVIVOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many definitions and phases of cancer survivorship. We define a cancer survivor as any person with cancer, starting from the moment of diagnosis. This is consistent with definitions from the National Coalition for Cancer Survivorship [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/5\">",
"     5",
"    </a>",
"    ] and the National Cancer Institute [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This overview addresses breast cancer survivors who have completed initial treatment for breast cancer (ie, surgery, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy) and who are without evidence of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346411030\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from American Society of Clinical Oncology (ASCO) suggest that patients with early stage breast cancer (tumor &lt;5 cm and fewer than four positive nodes) may follow-up exclusively with a primary care provider (PCP); for patients and clinicians who agree with this plan, care may be transferred approximately one year after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"     7",
"    </a>",
"    ]. In such cases, both the patient and the PCP should be advised of the appropriate follow-up and management strategy. Data are sparse to inform optimal follow-up of male breast cancer survivors; recommendations for women are usually applied to men, with modification as appropriate. Additional guidelines for posttreatment follow-up were made by the Institute of Medicine; these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030573#H418030573\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Guidelines for posttreatment follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients receiving adjuvant hormonal therapy, informed decisions regarding long-term options may necessitate periodic referral for oncology assessment since treatment strategies are evolving over time. Furthermore, input from an oncology specialist is warranted if there is suspicion or evidence of disease recurrence, or if questions arise regarding the safety of certain interventions (eg, vaginal estrogen in a patient who has severe atrophic vaginitis).",
"   </p>",
"   <p>",
"    Breast cancer survivors should receive ongoing age-appropriate screening studies and preventive care, consistent with recommendations for the general population, for conditions other than those related to breast cancer and its treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559591\">",
"    <span class=\"h1\">",
"     COMPONENTS OF FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541711608\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;History and physical examination have been the principal means of detecting a breast cancer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. We suggest that patients be seen every three to six months during the first three years after primary therapy, every 6 to 12 months for the next two years, and then annually (",
"    <a class=\"graphic graphic_table graphicRef61501 \" href=\"UTD.htm?5/39/5758\">",
"     table 1",
"    </a>",
"    ), consistent with American Society of Clinical Oncology (ASCO) 2012 guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"     7",
"    </a>",
"    ]. However, this schedule is arbitrary; no studies have evaluated the benefit of less frequent clinical visits in patients with low-risk disease or more frequent visits in those with higher-risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541711675\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the general components of a medical history, the breast cancer survivor should be screened for symptoms of local recurrence as well as metastatic disease. Any changes in the family history should be obtained, which may be important to discussions regarding genetic counseling. (See",
"    <a class=\"local\" href=\"#H346411104\">",
"     'Genetic counseling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The history should include any interval changes in the patient&rsquo;s social environment (including partner status, life events, living arrangements, and occupational issues) that may have arisen since the end of treatment.",
"   </p>",
"   <p>",
"    A review of systems should not only screen for metastatic disease but also may identify issues related to prior treatment. We suggest that the review of systems include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Constitutional symptoms",
"      </strong>",
"      &mdash; Anorexia, weight loss, malaise, fatigue, insomnia",
"     </li>",
"     <li>",
"      <strong>",
"       Bone health",
"      </strong>",
"      &mdash; Presence of pain and its characteristics (ie, location, character of pain [dull or aching], chronic or intermittent, associated symptoms, exacerbating factors and what provides relief)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary symptoms",
"      </strong>",
"      &mdash; Persistent cough or dyspnea (at rest or with exertion)",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic symptoms",
"      </strong>",
"      &mdash; Headache, nausea, vomiting, confusion, weakness, numbness or tingling",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal symptoms",
"      </strong>",
"      &mdash; Right upper quadrant pain, change in bowel habits, presence of bloody or tarry stools",
"     </li>",
"     <li>",
"      <strong>",
"       Genitourinary symptoms",
"      </strong>",
"      &mdash; Vaginal bleeding, pelvic pain, difficulty urinating",
"     </li>",
"     <li>",
"      <strong>",
"       Psychologic symptoms",
"      </strong>",
"      &mdash; Depression, anxiety",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Reproductive/Endocrine",
"       </strong>",
"      </span>",
"      symptoms",
"      &mdash; Hot flashes, dyspareunia, vaginal dryness, sexual dysfunction, fertility concerns (in women with intact ovarian function)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541711682\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that a complete physical examination be performed at each visit, which is consistent with ASCO guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"     7",
"    </a>",
"    ]. At a minimum, the examination should include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Examination of the breast, chest wall, and axilla",
"      </strong>",
"      &mdash; Thorough examination should be performed of the affected breast (if preserved) or chest wall, the contralateral side, the bilateral axillary regions, and the supraclavicular fossas. For those patients who underwent breast conserving treatment, providers should be comfortable examining the previously irradiated breast.",
"      <br/>",
"      <br/>",
"      The breast examination in patients who underwent adjuvant RT may not be helpful. In a review summarizing the results of seven randomized clinical trials, the sensitivity and specificity ranged from 29 to 74 percent and 17 to 30 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link\">",
"       \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Diagrams of the affected breast, including postoperative and postradiotherapy changes, can be helpful in documenting and following the examination over time.",
"      <br/>",
"      <br/>",
"      Evidence of local recurrence includes newly discovered lumps (on the skin, within the breast or the nodal regions). Other worrisome findings may include skin changes in the breast (",
"      <a class=\"graphic graphic_table graphicRef80826 \" href=\"UTD.htm?25/53/26459\">",
"       table 2",
"      </a>",
"      ). For women who have undergone mastectomy with or without breast reconstruction, the incision site and surrounding skin of the chest wall should be examined visually and palpated for abnormalities.",
"     </li>",
"     <li>",
"      <strong>",
"       Musculoskeletal examination",
"      </strong>",
"      &mdash; If lymphedema is suspected, examination of the arms should include circumferential measurement of the upper extremities bilaterally. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"       \"Clinical manifestations and diagnosis of lymphedema\"",
"      </a>",
"      .).",
"      <br/>",
"      <br/>",
"      In addition, palpation of the spine, sternum, ribs, and pelvis for bone tenderness should be routinely performed.",
"     </li>",
"     <li>",
"      <strong>",
"       Lung examination",
"      </strong>",
"      &mdash; Evaluation for breath sounds and percussion changes.",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominal examination",
"      </strong>",
"      &mdash; Evaluation for right upper quadrant tenderness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      organomegaly.",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac examination",
"      </strong>",
"      &mdash; Evaluation for of heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic examination",
"      </strong>",
"      &mdash; Evaluation of balance, gait, and sensory and motor function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gynecologic examination",
"      </strong>",
"      &mdash; Regular gynecologic follow-up should be performed for women who have not undergone total hysterectomy (",
"      <a class=\"graphic graphic_table graphicRef61501 \" href=\"UTD.htm?5/39/5758\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"       7",
"      </a>",
"      ]. This is particularly important in women who are receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      because of the increased risk for endometrial tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"       \"Managing the side effects of tamoxifen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560048\">",
"    <span class=\"h2\">",
"     Breast imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469430751\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the evidence is limited, surveillance mammography appears to be associated with a reduction in mortality among women of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. This was illustrated best in a 2008 case-control study that compared mammographic utilization in women over 65 years who died or did not die of breast cancer and who lived at least 30 months following breast cancer diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/16\">",
"     16",
"    </a>",
"    ]. Women who had undergone a surveillance mammogram within one year were less likely to die of breast cancer (odds ratio [OR] 0.83, 95% CI 0.72-0.95). &nbsp;",
"   </p>",
"   <p>",
"    The purpose of posttreatment mammographic surveillance is to detect ipsilateral local recurrences after breast conserving therapy (BCT), which develops in up to four percent of women treated for early breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, mammography is performed as surveillance for a contralateral breast cancer. There is a lack of high-quality evidence to inform the optimal timing and survival benefit of mammographic surveillance for detecting ipsilateral recurrence or a contralateral breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. For women in long-term follow-up, mammographic surveillance should be obtained annually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469430935\">",
"    <span class=\"h4\">",
"     Local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective trials that address the utility of mammography in the detection of local recurrence. Data from retrospective series suggest that mammography detects earlier lesions with a more favorable prognosis and that survival is improved in women whose lesions are detected mammographically as compared to those detected by other means [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, other data suggest that mammographic screening in women with a personal history of breast cancer performs less well (lower sensitivity and slightly lower specificity) than in women without such a history [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/23\">",
"     23",
"    </a>",
"    ]. In one study, women with a personal history of breast cancer had a higher rate of interval cancers compared to women without a history of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/23\">",
"     23",
"    </a>",
"    ]. Fortunately, the majority of both screen-detected and interval cancers were early stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469430942\">",
"    <span class=\"h4\">",
"     Contralateral breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that address the role of mammography or its impact on survival in detecting contralateral breast cancers. However, recommendations for mammographic surveillance are based upon the benefits seen in the general population without a history of breast cancer. In general, breast cancer survivors are higher-risk women than the general population, and it would seem reasonable to infer that they derive as much or even more benefit from mammography of the contralateral breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is indirect evidence from retrospective series that supports a beneficial impact for mammography of the contralateral breast [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. One study compared outcomes among a cohort of breast cancer survivors in which both physical examination and mammography were performed for posttreatment follow-up versus a separate cohort of women who were followed only by physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the frequency of contralateral breast cancer was similar in both groups, more recurrences were node-negative in the women with utilization of routine mammography (75 versus 57 percent, respectively). Furthermore, the contralateral tumors were more often smaller than 10 mm or in situ (noninvasive) (35 versus 7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559900\">",
"    <span class=\"h3\">",
"     Breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI is not routinely recommended for breast cancer survivors because of a lack of evidence to inform its role in this population. This was demonstrated in a 2012 systematic review that included 10 case series (n=494) on the role of MRI in the detection of a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/27\">",
"     27",
"    </a>",
"    ]. The sensitivity and specificity of MRI to detect recurrent breast cancer was no better than for mammography historically. However, breast MRI can be useful for patients suspected of a breast cancer recurrence when mammography (with or without breast ultrasound) is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Breast MRI is indicated in the follow-up of women at high risk for recurrent disease based on a known BRCA-mutation or strongly positive family history. However, this practice is extrapolated from the indications for breast MRI as a screening tool in high risk women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link&amp;anchor=H1486490#H1486490\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H463691260\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine use of breast ultrasound as part of surveillance is not recommended. The addition of breast ultrasound (US) to screening mammography was evaluated in a trial in which 2809 women with an elevated risk for breast cancer who were undergoing routine screening mammography were randomly assigned to mammography alone or with breast US [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/29\">",
"     29",
"    </a>",
"    ]. Compared to mammography alone, ultrasound plus mammography increased the diagnostic yield (from 8 to 12 per 1000 women, 95% CI 1.1 to 7.2) but also increased the rate of false positive results (4.4 versus 10.4 percent) and therefore lowered the positive predictive value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469431146\">",
"    <span class=\"h3\">",
"     Surveillance of reconstructed breasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have undergone mastectomy, surveillance is usually performed by physical examination. Routine mammographic imaging is technically limited in patients who have prosthetic implants and is generally not advocated. However, mammography is technically feasible following autogenous myocutaneous flap reconstruction, particularly following TRAM (transverse rectus abdominis musculocutaneous) or perforator flap reconstruction, because abdominal adipose tissue forms the bulk of the reconstructed breast [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/30\">",
"     30",
"    </a>",
"    ]. Although the available data are sparse, and there is no consensus on this issue, some institutions image TRAM-reconstructed breasts using mammography (\"TRAMogram\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"     \"Breast reconstruction in women with breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Findings on imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only place where cancer can occur is either right below the skin in the subcutaneous tissue or just over the pectoralis muscle. Physical examination remains the cornerstone of detection of recurrent breast cancer after reconstruction, and other modalities such as MRI should be used only as adjuncts to clarify any physical findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H48#H48\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Posttreatment surveillance of the reconstructed breast'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2692716\">",
"    <span class=\"h3\">",
"     Discontinuing breast imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued screening mammography is warranted for older survivors with reasonable functional status and life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/31\">",
"     31",
"    </a>",
"    ]. The available data suggest that surveillance mammography reduces the risk of death from breast cancer, even among older women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study evaluated over 1800 women 65 years and older with stage I and II breast cancer and reported that each additional mammogram was associated with a significant reduction in the risk of dying from breast cancer (odds ratio 0.69, 95% CI 0.52-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/15\">",
"     15",
"    </a>",
"    ]. A similar conclusion was reached in a study from the Surveillance, Epidemiology and End Results (SEER)-Medicare database [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346411104\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer survivors who have not already pursued genetic testing may be appropriate candidates for testing. BRCA testing is an especially important consideration for men, and for women diagnosed under the age of 40, or with Ashkenazi heritage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a strong family history of breast or ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/31\">",
"     31",
"    </a>",
"    ]. Prior to testing, it is important that patients be counseled about the potential ramifications of test results for themselves and their families, both medically and psychosocially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H7#H7\">",
"     \"Breast cancer in men\", section on 'Inherited conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rarer genetic syndromes that predispose to breast cancer and for which testing can be performed, depending on family and personal history of a variety of cancers, include Li Fraumeni and Cowden syndromes. A genetic counselor can help to discern whether such testing might be in order. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing of the breast cancer survivor is important, particularly in order to facilitate testing in other family members. Once a particular mutation has been identified, testing other family members is technically straightforward. While it is possible to begin the genetic testing process in an unaffected individual, there is a greater chance that these results will be inconclusive. Therefore, the breast cancer survivor should be tested, particularly if her own children and first-degree relatives are also interested in their personal genetic susceptibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H27#H27\">",
"     \"Genetic counseling and testing\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541712004\">",
"    <span class=\"h2\">",
"     Role of laboratory and imaging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologic surveillance is not indicated for asymptomatic breast cancer survivors. This was demonstrated in a 2005 meta-analysis of two randomized trials that compared routine follow-up (regular physical examination and mammography) versus intensive surveillance (including radiological and laboratory testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no difference between groups in overall survival (hazard ratio [HR] 0.96, 95% CI 0.80-1.15) or disease-free survival (HR 0.84, 95% CI 0.71-1.00).",
"   </p>",
"   <p>",
"    Early diagnosis of metastatic disease, based on imaging alone and prior to onset of clinical signs or symptoms, may result in earlier intervention, with associated toxicities, but does not improve survival. Although a small percentage of patients with limited metastatic disease (eg, isolated pulmonary or liver metastases) may be treated with a multimodality approach, whether such patients are best identified by intensive posttreatment surveillance is unknown. Furthermore, laboratory and imaging tests used for surveillance have significant false positive and false negative rates. The unnecessary additional testing generated by a false positive result and the misleading reassurance generated by a false negative test can adversely affect the breast cancer survivor.",
"   </p>",
"   <p>",
"    Therefore, we recommend",
"    <strong>",
"     against",
"    </strong>",
"    performing the following tests in asymptomatic women including (",
"    <a class=\"graphic graphic_table graphicRef61501 \" href=\"UTD.htm?5/39/5758\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Liver function tests",
"      </strong>",
"      &mdash; Routine liver function tests are falsely elevated in up to 80 percent of women without liver metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Serum tumor markers",
"      </strong>",
"      &mdash; A number of serum markers are available that can detect early breast cancer recurrence, including CA 15-3, CEA (carcinoembryonic antigen), and CA 27.29 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]. These biochemical markers of breast cancer increase in conjunction with advancing primary disease stage and reflect the total body burden of disease (",
"      <a class=\"graphic graphic_table graphicRef59985 \" href=\"UTD.htm?13/6/13419\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]. However, they are neither sensitive nor specific for breast cancer relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Therefore, measurement of serum tumor markers should only be used to monitor treatment response of patients with metastatic breast cancer, in the absence of readily measurable advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Chest imaging",
"      </strong>",
"      &mdash; Neither chest X-rays nor computed tomography (CT) is recommended to screen for lung metastases in the asymptomatic patient [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. In one series of 416 patients who were undergoing surveillance with routine chest imaging after completing primary treatment for breast cancer, only nine patients had isolated pulmonary metastases. [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bone scan and serum alkaline phosphatase",
"      </strong>",
"      &mdash; There is no evidence that early detection of bone metastases changes the clinical course of the disease. Metastases to bone are almost always diagnosed by symptoms, even when patients undergo routine surveillance with bone scans [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/49-52\">",
"       49-52",
"      </a>",
"      ]. Bone scans have an estimated sensitivity and specificity for detecting bone metastases of approximately 86 and 81 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Alkaline phosphatase is neither sensitive nor specific for bone metastases. In a series of 1601 patients with node-positive breast cancer, alkaline phosphatase was only elevated in one-half of those patients who had known skeletal metastases, while the test was abnormal in 28 percent of those without bone metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominopelvic imaging",
"      </strong>",
"      &mdash; Neither liver ultrasound nor abdominopelvic CT scans is recommended as a routine component of posttreatment surveillance [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. In one large series of over 2400 patients that included 6628 pelvic CT scans performed over a nine-year period, pelvic metastases were the only site of metastatic disease in 13 (0.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/55\">",
"       55",
"      </a>",
"      ]. However, the findings led to over 200 additional radiographic and 50 surgical procedures, of which 84 percent yielded benign or negative results.",
"     </li>",
"     <li>",
"      <strong>",
"       PET scanning",
"      </strong>",
"      &mdash; There is no role for positron emission tomography (PET) scan in posttreatment follow-up. In retrospective cohort studies and a meta-analysis of 16 studies, PET scanning has been consistently more sensitive than conventional imaging and serum tumor markers for early diagnosis of recurrent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/57-59\">",
"       57-59",
"      </a>",
"      ]. However, the impact on survival and quality of life has not been addressed, and it seems unlikely that this approach would provide a survival or quality of life benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541711995\">",
"    <span class=\"h1\">",
"     PROMOTING A HEALTH LIFESTYLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often ask what they can do to improve their overall outcome from breast cancer. Lifestyle modification can be an empowering and effective way to boost physical and mental health in breast cancer survivors, and possibly to improve outcomes. Observational data suggest that exercise, avoidance of obesity, and minimization of alcohol intake are associated with a decreased risk of breast cancer recurrence and death in survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/60-63\">",
"     60-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H128691\">",
"    <span class=\"h2\">",
"     Physical activity, diet, and body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet, physical activity, and weight are collectively considered energy balance factors because they describe the relationship between energy consumed (diet), energy expended (physical activity), and energy stored (adiposity). They have each been linked to cancer outcomes, particularly in survivors of breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H128834\">",
"    <span class=\"h2\">",
"     Soy and other complementary therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;One nutritional issue of interest to breast cancer survivors is the impact of soy products (which contain phytoestrogens) on breast cancer recurrence rates. Although there is no convincing evidence that soy affects the risk of recurrence, the theoretical risk that phytoestrogens could stimulate the growth of hormonally sensitive cancers raises the concern that high soy intake could be dangerous. Thus, moderation of soy intake is generally suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, the safety and efficacy of many other complementary therapies including mistletoe, high doses of vitamins, and trace elements like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , zinc, and copper remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link\">",
"     \"Complementary and alternative therapies for cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H128815\">",
"    <span class=\"h2\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence that alcohol is associated with an increase in the risk of recurrence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/63,65-67\">",
"     63,65-67",
"    </a>",
"    ]. In the largest study, 1897 female breast cancer survivors (on average two years post diagnosis) participated in the Life After Cancer Epidemiology (LACE) study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/63\">",
"     63",
"    </a>",
"    ]. Those who drank &ge;6 grams of alcohol daily (equivalent to at least three to four alcoholic drinks per week) had significantly higher rates of recurrence (hazard ratio [HR] 1.35, 95% CI 1.0 to 1.83) and death due to breast cancer (HR 1.51, 95% CI 1.0 to 2.29) than those who drank &lt;0.5 grams daily. Overweight and postmenopausal women seemed to experience the greatest harm from alcohol intake as measured by breast cancer recurrence risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346411119\">",
"    <span class=\"h1\">",
"     SEXUAL AND REPRODUCTIVE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H463691037\">",
"    <span class=\"h2\">",
"     Sexual health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopausal symptoms that result from chemotherapy (in premenopausal women) and hormonal therapy (regardless of menopausal status) may make sexual activity less enjoyable and even painful. The psychological sequelae of a breast cancer diagnosis can include strains on relationships and changes in body image, both of which can be detrimental to sexual functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/68\">",
"     68",
"    </a>",
"    ]. Sexual dysfunction is associated with depression in breast cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/69\">",
"     69",
"    </a>",
"    ]. It is important for physicians to routinely ask breast cancer survivors about their sexual functioning. Referral to a sexual health",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mental health expert may be helpful.",
"   </p>",
"   <p>",
"    Interventions for women who report dyspareunia or difficulty reaching orgasm may benefit from one or more of the following: vaginal dilators, lubricants, and counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/70\">",
"     70",
"    </a>",
"    ]. Local hormonal therapy (ie, vaginal estrogen tablets or creams) may provide relief of symptoms, but its use is controversial, particularly among women with a history of hormone receptor-positive breast cancer.",
"   </p>",
"   <p>",
"    Although one study demonstrated that vaginal estrogen results in a detectable increase in circulating estradiol levels among women taking an aromatase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/71\">",
"     71",
"    </a>",
"    ], another study suggests that vaginal estrogen therapy does not result in an increased risk of recurrence in women taking endocrine therapy. The impact of vaginal estrogen on recurrence risk was evaluated among 917 women with a breast cancer recurrence (cases) who were compared to 8885 women with breast cancer in remission (controls, matched for age and initial endocrine treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/72\">",
"     72",
"    </a>",
"    ]. The overall rate of vaginal estrogen usage was low (less than three percent) and was predominantly administered to women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of concomitant vaginal estrogen administration (with endocrine therapy) was similar among cases and controls (2.1 versus 2.8%, respectively) suggesting that concomitant administration is not associated with an increased risk of recurrence (RR 0.78, 95% CI 0.48-1.25).",
"     </li>",
"     <li>",
"      The rate of sequential use of vaginal estrogen following completion of endocrine therapy was also similar (0.2% in both cases and controls) suggesting there is no increase in the risk of recurrence (RR 0.97, 95% CI 0.22-4.18).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of this low quality evidence, a decision to use vaginal estrogens must be individualized, taking into account tumor characteristics, current symptoms, and the risks and potential benefits of therapy, with input from both the primary oncologist and primary care provider (PCP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346411135\">",
"    <span class=\"h2\">",
"     Fertility and pregnancy after breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young breast cancer survivors may experience infertility after breast cancer due to chemotherapy-related gonadotoxicity and the delay in childbearing required when women are taking the recommended five years of hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with a history of breast cancer, a subsequent pregnancy does not appear to compromise survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. This was demonstrated in a 2011 meta-analysis of 14 case-control studies that evaluated the impact of pregnancy on the overall survival of women with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/74\">",
"     74",
"    </a>",
"    ]. Compared to women who did not get pregnant, those who became pregnant had a 40 percent reduction in the risk of death (pooled risk ratio [PRR] 0.59, 90% CI 0.50-0.70). This outcome is likely explained by a selection bias known as the &ldquo;healthy mother effect&rdquo;, such that only healthy breast cancer survivors were able to conceive and carry a pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, a study presented at the 2012 European Breast Cancer Conference suggests that pregnancy after breast cancer is safe regardless of estrogen receptor status [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link&amp;anchor=H84662782#H84662782\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\", section on 'Pregnancy after breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While some experts recommend that patients wait two years after completing adjuvant therapy before attempting conception in order to avoid pregnancy during the time of highest relapse risk, limited data suggest that pregnancy sooner is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Reassuringly, prior breast cancer treatments do not appear to increase the risk of congenital malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link&amp;anchor=H84662782#H84662782\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\", section on 'Pregnancy after breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269850350\">",
"    <span class=\"h3\">",
"     Contraception after breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;While women with a history of breast cancer may wish to preserve fertility, they may not have an imminent desire to become pregnant. Potential options for contraception include barrier methods (eg, diaphragms, condoms) and the copper intrauterine device (IUD). A more extensive discussion of the topic of contraception is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The safety and efficacy of hormonal contraception has not been well studied in women with breast cancer, as these women have traditionally been excluded from studies of hormonal contraceptives. The levonorgestrel-releasing intrauterine contraception device (LNG-IUD) has been evaluated in women with a history of breast cancer, although primarily as a method of endometrial protection from the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    rather than as a contraceptive modality. Data are limited and inconclusive, but suggest an increased risk of cancer recurrence despite a low rate of systemic hormone absorption. This was shown in one retrospective cohort study of breast cancer survivors that evaluated the risk of cancer recurrence among cases (LNG-IUD users, n=79) and controls (those who did not use LNG-IUD, n=120) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/80\">",
"     80",
"    </a>",
"    ]. The rate of breast cancer recurrence was higher in cases compared to matched controls (22 versus 17 percent, OR 1.86, 95% 0.86-4.00), although the difference was not statistically significant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link&amp;anchor=H9482672#H9482672\">",
"     \"Managing the side effects of tamoxifen\", section on 'Endometrial protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of prospective data, we agree with the World Health Organization guidelines for medical eligibility for contraceptive use and suggest avoiding hormonal contraception in women with a current or past history of breast cancer (particularly in those with hormone receptor-positive disease) (",
"    <a class=\"graphic graphic_table graphicRef60832 \" href=\"UTD.htm?33/28/34255\">",
"     table 4",
"    </a>",
"    ). Clinicians should discuss the use of a nonhormonal contraceptive method (condom, diaphragm, copper IUD) and help the woman choose the method most consistent with her lifestyle and beliefs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12070561\">",
"    <span class=\"h1\">",
"     COORDINATION OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If agreed upon by the patient, the treating oncologist, and the PCP, shared care would provide treatment summary information and a plan for follow-up care to both the patient and the PCP. The level of shared follow-up by the oncology specialist and PCP could depend upon patient and provider preferences. Communication between the PCP and subspecialist is vital given that uncertainties about physician roles and responsibilities can lead to deficiencies in care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/12/5322/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030689#H418030689\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Coordination of care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H566671\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Essential elements of management for breast cancer survivors who have completed active treatment and have no evidence of disease are cancer surveillance, encouragement of adherence with ongoing treatment and lifestyle recommendations, treatment of medical and psychosocial consequences of cancer and its therapy, and care coordination between specialists and primary care providers. (See",
"      <a class=\"local\" href=\"#H346411016\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivor follow-up should include updated history, regular physical examination, and breast imaging (ie, mammography). The follow-up should not only focus on cancer surveillance, but also on any late-treatment related complications, psychosocial issues, and occupational problems. (See",
"      <a class=\"local\" href=\"#H12559591\">",
"       'Components of follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women with breast cancer should be counselled about the role of genetic testing and counseling. (See",
"      <a class=\"local\" href=\"#H346411104\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory studies or radiologic imaging to screen for distant recurrence in asymptomatic patients should not be performed. (See",
"      <a class=\"local\" href=\"#H541712004\">",
"       'Role of laboratory and imaging evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diet and exercise can promote well-being and may improve survival. All breast cancer survivors should pursue a healthy lifestyle that includes following a prudent diet, pursuing or maintaining an active exercise program, minimizing alcohol intake, and refraining from smoking. (See",
"      <a class=\"local\" href=\"#H541711995\">",
"       'Promoting a health lifestyle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment may affect many aspects of sexuality, and breast cancer survivors should be routinely questioned about concerns related to sexual health and counseled or referred as needed. (See",
"      <a class=\"local\" href=\"#H463691037\">",
"       'Sexual health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although data are limited, studies do not indicate increased risk of recurrence for survivors who become pregnant or an impact on pregnancy outcomes. (See",
"      <a class=\"local\" href=\"#H346411119\">",
"       'Sexual and reproductive issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with breast cancer who wish to preserve fertility but delay pregnancy, we suggest not administering hormonal contraception (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Physicians should counsel women about methods most consistent with their lifestyle and beliefs. Alternative forms of contraception include copper IUD and barrier methods. (See",
"      <a class=\"local\" href=\"#H269850350\">",
"       'Contraception after breast cancer'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      A variety of clinicians may adequately follow women after their primary therapy for breast cancer. Clinicians should be experienced in the surveillance of these patients, the complications that may arise from treatment, and in breast examination, including the examination of irradiated breasts. A shared care model that integrates both specialists and primary care providers on ongoing follow-up care may provide the best adherence to guidelines for recommended care; but communication and coordination of care is required. (See",
"      <a class=\"local\" href=\"#H12070561\">",
"       'Coordination of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     GLOBOCAN 2008 Update file://www.iarc.fr/en/media-centre/iarcnews/2011/globocan2008-prev.php (Accessed on July 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/2\">",
"      Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/3\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/4\">",
"      Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009; 27:2489.",
"     </a>",
"    </li>",
"    <li>",
"     Information about the National Coalition for Cancer survivorship available online at file://www.canceradvocacy.org/about/ (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     Survivor. Dictionary of Cancer Terms. National Cancer Institute. file://www.cancer.gov/dictionary?cdrid=450125 (Accessed on July 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/7\">",
"      Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2013; 31:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/8\">",
"      de Bock GH, Bonnema J, van der Hage J, et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol 2004; 22:4010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/9\">",
"      Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 2007; 97:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/10\">",
"      Lu W, de Bock GH, Schaapveld M, et al. The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer 2011; 47:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/11\">",
"      Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer 2007; 96:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/12\">",
"      Loomer L, Brockschmidt JK, Muss HB, Saylor G. Postoperative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature. Cancer 1991; 67:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/13\">",
"      Pace BW, Tinker MA. Follow-up of patients with breast cancer. Clin Obstet Gynecol 1994; 37:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/14\">",
"      Temple LK, Wang EE, McLeod RS. Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ 1999; 161:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/15\">",
"      Lash TL, Fox MP, Buist DS, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 2007; 25:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/16\">",
"      Schootman M, Jeffe DB, Lian M, et al. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat 2008; 111:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/17\">",
"      Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J 2006; 12:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/18\">",
"      Yang SH, Yang KH, Li YP, et al. Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2008; 19:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/19\">",
"      Grunfeld E, Noorani H, McGahan L, et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 2002; 11:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/20\">",
"      Orel SG, Fowble BL, Solin LJ, et al. Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method. Radiology 1993; 188:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/21\">",
"      Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/22\">",
"      Montgomery DA, Krupa K, Jack WJ, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 2007; 96:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/23\">",
"      Houssami N, Abraham LA, Miglioretti DL, et al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 2011; 305:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/24\">",
"      Mellink WA, Holland R, Hendriks JH, et al. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991; 67:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/25\">",
"      Gutter Z. Cancer of the remaining breast: radiologic contribution to diagnosis. Can Med Assoc J 1976; 114:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/26\">",
"      Senofsky GM, Wanebo HJ, Wilhelm MC, et al. Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer 1986; 57:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/27\">",
"      Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol 2012; 19:3035.",
"     </a>",
"    </li>",
"    <li>",
"     BC Cancer Agency: Clinical indications for breast MRI. file://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Diagnosis/MRI.htm (Accessed on August 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/29\">",
"      Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012; 307:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/30\">",
"      Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 2007; 120:1125.",
"     </a>",
"    </li>",
"    <li>",
"     www.nccn.org (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/32\">",
"      Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005; :CD001768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/33\">",
"      Schreve RH, Terpstra OT, Ausema L, et al. Detection of liver metastases. A prospective study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography. Br J Surg 1984; 71:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/34\">",
"      Kemeny MM, Sugarbaker PH, Smith TJ, et al. A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 1982; 195:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/35\">",
"      Wiener SN, Sachs SH. An assessment of routine liver scanning in patients with breast cancer. Arch Surg 1978; 113:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/36\">",
"      Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/37\">",
"      Molina R, Zan&oacute;n G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/38\">",
"      J&auml;ger W, Kr&auml;mer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl 1995; 221:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/39\">",
"      Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/40\">",
"      Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/41\">",
"      Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006; 6:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/42\">",
"      Valenzuela P, Mateos S, Tello E, et al. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003; 24:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/43\">",
"      Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/44\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/45\">",
"      Hurria A, Leung D, Trainor K, et al. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag 2003; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/46\">",
"      Kokko R, Hakama M, Holli K. Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Res Treat 2003; 81:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/47\">",
"      Mehta VK, Goffinet DR. Unsuspected abnormalities noted on CT treatment-planning scans obtained for breast and chest wall irradiation. Int J Radiat Oncol Biol Phys 2001; 49:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/48\">",
"      Rutgers EJ, van Slooten EA, Kluck HM. Follow-up after treatment of primary breast cancer. Br J Surg 1989; 76:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/49\">",
"      Hannisdal E, Gundersen S, Kval&oslash;y S, et al. Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer 1993; 29A:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/50\">",
"      Tomin R, Donegan WL. Screening for recurrent breast cancer--its effectiveness and prognostic value. J Clin Oncol 1987; 5:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/51\">",
"      Wickerham L, Fisher B, Cronin W. The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat 1984; 4:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/52\">",
"      Pedrazzini A, Gelber R, Isley M, et al. First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol 1986; 4:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/53\">",
"      Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing &sup1;FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/54\">",
"      Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994; 271:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/55\">",
"      Drotman MB, Machnicki SC, Schwartz LH, et al. Breast cancer: assessing the use of routine pelvic CT in patient evaluation. AJR Am J Roentgenol 2001; 176:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/56\">",
"      Kauczor HU, Voges EM, Wieland-Schneider C, et al. Value of routine abdominal and lymph node sonography in the follow-up of breast cancer patients. Eur J Radiol 1994; 18:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/57\">",
"      Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/58\">",
"      Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/59\">",
"      Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/60\">",
"      Friedenreich CM, Gregory J, Kopciuk KA, et al. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 2009; 124:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/61\">",
"      Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/62\">",
"      Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/63\">",
"      Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol 2010; 28:4410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/64\">",
"      Gerber B, Scholz C, Reimer T, et al. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 2006; 95:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/65\">",
"      Hebert JR, Hurley TG, Ma Y. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat 1998; 51:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/66\">",
"      Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat 1999; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/67\">",
"      Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/68\">",
"      Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/69\">",
"      Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J 2005; 11:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/70\">",
"      Hickey M, Saunders C, Partridge A, et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008; 19:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/71\">",
"      Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012; 285:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/72\">",
"      Le Ray I, Dell'Aniello S, Bonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012; 135:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/73\">",
"      Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16 Suppl 2:S175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/74\">",
"      Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/75\">",
"      Calhoun K, Hansen N. The effect of pregnancy on survival in women with a history of breast cancer. Breast Dis 2005; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/76\">",
"      Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/77\">",
"      Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 2010; 65:786.",
"     </a>",
"    </li>",
"    <li>",
"     Azim H. Pregnancy following estrogen receptor-positive breast cancer is safe- results from a large multi-center case-control study. Presented at the Eighth Annual European Breast Cancer Conference, Vienna, Austria. 3/21/2012. (Abstr 21).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/79\">",
"      Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990; 65:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/12/5322/abstract/80\">",
"      Trinh XB, Tjalma WA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15781 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5322=[""].join("\n");
var outline_f5_12_5322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H566671\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346411016\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541710487\">",
"      DEFINING A CANCER SURVIVOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346411030\">",
"      GUIDELINES FOR POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12559591\">",
"      COMPONENTS OF FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541711608\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541711675\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541711682\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H560048\">",
"      Breast imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H469430751\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H469430935\">",
"      Local recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H469430942\">",
"      Contralateral breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12559900\">",
"      - Breast MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H463691260\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H469431146\">",
"      - Surveillance of reconstructed breasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2692716\">",
"      - Discontinuing breast imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346411104\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541712004\">",
"      Role of laboratory and imaging evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541711995\">",
"      PROMOTING A HEALTH LIFESTYLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H128691\">",
"      Physical activity, diet, and body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H128834\">",
"      Soy and other complementary therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H128815\">",
"      Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346411119\">",
"      SEXUAL AND REPRODUCTIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H463691037\">",
"      Sexual health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346411135\">",
"      Fertility and pregnancy after breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H269850350\">",
"      - Contraception after breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12070561\">",
"      COORDINATION OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566671\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/39/5758\" title=\"table 1\">",
"      Breast cancer surveillance guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/53/26459\" title=\"table 2\">",
"      Signs symptoms breast CA recur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/6/13419\" title=\"table 3\">",
"      Tumor markers breast CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/28/34255\" title=\"table 4\">",
"      WHO MEC for reproductive tract infections and disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_12_5323="Etiologies of bradyarrhythmias";
var content_f5_12_5323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major etiologies of bradyarrhythmias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sinus bradycardia and its variants - including sinoatrial block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Atrioventricular heart block or dissociation - can occur with sinus rhythm or atrial fibrillation or flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Second or third degree AV block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isorhythmic AV dissociation and related variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wandering atrial pacemaker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Junctional (AV nodal) escape rhythms - can occur with sinus rhythm or atrial fibrillation or flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular escape (idioventricular) rhythms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5323=[""].join("\n");
var outline_f5_12_5323=null;
var title_f5_12_5324="Clinical practice guidelines";
var content_f5_12_5324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical practice guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Standard",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Transparency",
"       </td>",
"       <td>",
"        Guidelines should include an explicit description of process and funding.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Conflict of interest",
"       </td>",
"       <td>",
"        Conflicts of interest for the guidelines development group should be managed by reporting, exclusion, and divestments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Members of the guidelines development group",
"       </td>",
"       <td>",
"        The group should be multidisciplinary and balanced.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Review of the literature",
"       </td>",
"       <td>",
"        The guideline should be based on systematic reviews of the literature.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Rating strength of evidence and recommendations",
"       </td>",
"       <td>",
"        Each recommendation should be accompanied by the underlying reasoning, potential benefits and harms, the evidence and its quality, the contribution of values and experience, rating of the level of confidence in the evidence and the strength of the recommendation, and differences of opinion regarding recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Presentation of recommendations",
"       </td>",
"       <td>",
"        The guideline should state precisely the recommended actions, when they should be performed, and how they could be measured for evaluation of compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. External review",
"       </td>",
"       <td>",
"        The guidelines should be reviewed by the full spectrum of relevant stakeholders. The general public should have an opportunity to review the guidelines before they are final.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Updating",
"       </td>",
"       <td>",
"        Guidelines should state date of publication and evidence review and be updated when new, clinically-important evidence is available.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from the consensus report: Clinical Practice Guidelines We Can Trust. Institute of Medicine of The National Academies. Report available at:",
"     <a href=\"file://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx\" target=\"_blank\">",
"      file://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5324=[""].join("\n");
var outline_f5_12_5324=null;
var title_f5_12_5325="Staph IE medical Rx in IDU";
var content_f5_12_5325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical management of staphylococcus aureus infective endocarditis in injection drug users",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number with IE",
"       </td>",
"       <td class=\"subtitle1\">",
"        Valve involved",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobial regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcomes/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abrams et al, 1979",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        Right-sided (20), left-sided (2), both (3)",
"       </td>",
"       <td>",
"        Beta-lactam x 4 wks vs. beta-lactam x 4 wks plus gentamicin x 2 wks",
"       </td>",
"       <td>",
"        No treatment failures in either group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parker et al, 1980",
"       </td>",
"       <td>",
"        33 (29 with IDU)",
"       </td>",
"       <td>",
"        Right-sided (29), left-sided (4)",
"       </td>",
"       <td>",
"        Multiple IV regimens (mean duration 16 days), then multiple single PO regimens (mean duration 26 days)",
"       </td>",
"       <td>",
"        100 percent cure rate at 6 months; all patients male; mean total duration of therapy 42 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chambers et al, 1988",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Nafcillin plus tobramycin x 2 wks (vancomycin instead of nafcillin in 3 penicillin allergic patients)",
"       </td>",
"       <td>",
"        47 of 50 (94 percent) cured at 2 wks with nafcillin/ tobramycin, 1 of 3 (33 percent) with vancomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dworkin et al, 1989",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Ciprofloxacin (IV, then PO) plus rifampin x 4 wks",
"       </td>",
"       <td>",
"        10 of 14 completed therapy, all cured at 4 wks of follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Markowitz et al, 1992",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (TMP-SMX) vs. vancomycin",
"       </td>",
"       <td>",
"        7 of 11 (64 percent) cured with TMP-SMX vs. 11 of of 12 (92 percent) with vancomycin; no treatment failures for MRSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Torres-Tortosa et al, 1994",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Cloxacillin plus amikacin x 2 wks; chosen for good prognosis",
"       </td>",
"       <td>",
"        67 of 72 (93 percent) cured; 24 percent mortality in those with poor prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fortun et al, 1995",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Cloxacillin plus gentamicin x 2 wks vs. teicoplanin x 28 days",
"       </td>",
"       <td>",
"        Study stopped early due to high rate of failure in teicoplanin arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heldman et al, 1996",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        Right-sided",
"       </td>",
"       <td>",
"        Ciprofloxacin PO plus rifampin x 4 wks vs. oxacillin or vancomycin x 28 days plus gentamicin x 5 days",
"       </td>",
"       <td>",
"        Only 44 patients available for test of cure, bacteriologic",
"cure in 18 of 19 (95 percent) with PO regimen, 22 of 25 (88 percent)",
"with IV; definite IE in 15 patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Ribera et al, 1996",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        90",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Right-sided",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cloxacillin x 2 wks vs. cloxacillin x 2 wks plus gentamicin x 7 days",
"       </td>",
"       <td>",
"        <strong>",
"         Intention-to-treat analysis:",
"        </strong>",
"        34 to 45 (76 percent) cured with cloxacillin vs. 31 to 45 (69 percent) with cloxacillin/gentamicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Efficacy analysis:",
"        </strong>",
"        34 to 38 (89 percent) cure rate with monotherapy vs. 31 of 36 (86 percent) with combination regimen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5325=[""].join("\n");
var outline_f5_12_5325=null;
var title_f5_12_5326="Causes of bronchiolitis";
var content_f5_12_5326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical syndromes associated with bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inhalation injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic fume inhalation (eg, silo fillers)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grain (organic) or mineral dusts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritant gases or fumes (eg, welding)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cigarette smoke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Volatile flavoring agents (popcorn factory)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Postinfectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Respiratory syncytial virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Adenovirus or rhinovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Influenza or parainfluenza",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Measles or mumps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Varicella zoster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Human immunodeficiency virus (HIV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Other infectious agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mycoplasma pneumoniae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Legionella pneumophila",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Serratia marcescens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bordetella pertussis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Streptococcus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nocardia asteroides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pneumocystis jirovecii (P. carinii)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drug-induced reactions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hexamethonium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            L-tryptophan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Busulfan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Free-base cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gold",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephalosporin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfasalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acebutolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulindac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat poisoning",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            No associated diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cryptogenic constrictive bronchiolitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Respiratory bronchiolitis-associated interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cryptogenic organizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diffuse panbronchiolitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Associated with other diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Associated with organ transplantation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bone marrow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Heart-lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Associated with connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sjogren's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Polymyositis/dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Drug reaction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Distal to bronchial obstruction, \"obstructive pneumonitis\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypersensitivity pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ulcerative colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chronic eosinophilic pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Rare associations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Irradiation or aspiration pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Idiopathic pulmonary fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Malignant histiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Adult respiratory distress syndrome (ARDS)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Vasculitis, especially granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Chronic thyroiditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Primary biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Aspiration pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Lysinuric protein intolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Paraneoplastic pemphigus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Ataxia-telangiectasia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5326=[""].join("\n");
var outline_f5_12_5326=null;
var title_f5_12_5327="MDI in-line spacer";
var content_f5_12_5327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inline metered dose inhaler spacing device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Using a chamber results in a four- to six-fold greater delivery of aerosol than actuation into a connector attached directly to the endotracheal tube, or into an inline device that lacks a chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_12_5327=[""].join("\n");
var outline_f5_12_5327=null;
